Research AppraisalRandomised Controlled Trial

A multifunctional porous interface bridging 3D architected electronics with skin

Science advancesShen, Zhangming, Cheng, Xu, Luo, Xiaobin et al.10 July 2026DOI

Clinical Snapshot

40CEBM
Evidence: InsufficientRandomised Controlled Trial

PICO Framework

P — PopulationPreclinical animal models (in vivo scald wound models) and human skin (ex vivo/wearable device characterisation); implicitly targeting patients requiring wound healing, health monitoring, or skin disease treatment
I — InterventionMultifunctional microporous interface integrating 3D architected flexible electronics with skin, incorporating multimodal sensing, on-demand drug delivery, moisture permeability, thermal buffering, and impact mitigation capabilities
C — ComparatorConventional non-porous or 2D flexible electronic interfaces; no formal randomised comparator group described for in vivo wound healing experiments
O — OutcomesPrimary: scald wound healing acceleration in vivo; Secondary: mechanical resilience (elastic stretchability, stiffness reduction), electrical reliability under deformation, moisture permeability, thermal buffering, impact mitigation, and drug delivery performance

Bottom Line

This proof-of-concept engineering study from Tsinghua University introduces a microporous interface designed to bridge 3D flexible electronic devices with skin, aiming to enable long-term comfortable wearable health monitoring and wound therapy. The innovation lies in the engineered microporous network architecture, which the authors report simultaneously enhances mechanical stretchability, electrical reliability, moisture permeability, thermal buffering, impact resistance, and drug delivery capacity. A prototype closed-loop wound patch demonstrated accelerated scald wound healing in an animal model. While the conceptual framework is scientifically compelling and addresses a genuine unmet need in wearable medical technology, this study is firmly preclinical. No quantitative outcome data, confidence intervals, or statistical analyses are reported in the abstract. The in vivo wound healing claim lacks methodological transparency regarding animal model details, sample sizes, blinding, or comparator conditions. Clinicians should recognise this as early-stage translational research (CEBM Level 5) with no current applicability to patient care. Substantial further work — including biocompatibility testing, long-term stability studies, and randomised clinical trials — is required before this technology could be considered for clinical use or TGA registration in Australia.

Evidence: Insufficient

Key Findings

  • P Value: Not reported

  • Effect Size: Not reported quantitatively in the abstract; described qualitatively as 'markedly accelerating' wound healing

  • Primary Outcome: Accelerated scald wound healing in vivo using a 3D closed-loop wound administration patch with multimodal sensing and on-demand therapy capabilities

  • Nnt Or Sensitivity: Not applicable at this preclinical stage; no NNT, sensitivity, specificity, or hazard ratio data available. Mechanical performance metrics (stretchability enhancement, stiffness reduction) are referenced but not quantified in the abstract

  • Confidence Interval: Not reported

Clinical Application

Clinical feasibility is highly speculative at this stage. Significant barriers include: manufacturing complexity and scalability of 3D microporous electronic architectures; regulatory approval processes for combination devices (drug-device combinations face dual regulatory pathways); integration with existing wound care workflows; healthcare professional training requirements; device sterilisation and single-use versus reusable classification; and cost-effectiveness relative to established wound care products. The technology readiness level (TRL) appears to be approximately TRL 3-4 (proof of concept demonstrated in laboratory/animal setting). In Australia, this class of device would require TGA registration as a medical device under the Therapeutic Goods Act 1989, with classification likely as a Class IIb or Class III device given the drug delivery and active therapeutic components. The drug delivery component would additionally require evaluation under the Therapeutic Goods (Medical Devices) Regulations 2002 for combination products. PBS listing for wound care consumables is governed by the Prostheses List Advisory Committee (PLAC) and would require demonstrated clinical and cost-effectiveness data not yet available. RACGP and AWMA (Australian Wound Management Association) guidelines for wound care currently recommend evidence-based dressings and debridement strategies; this technology is not yet positioned for guideline inclusion. The Australian healthcare system's emphasis on cost-effectiveness through HTA processes (MSAC) would require robust RCT data before public funding consideration. Not currently applicable to any clinical population. Conceptually relevant to patients with acute thermal wounds (scalds, burns), chronic wounds requiring continuous monitoring, patients requiring long-term wearable health monitoring devices, and potentially those with skin diseases requiring topical drug delivery. Future applicability would depend on successful completion of biocompatibility testing, regulatory approval, and clinical trials.

Abstract

Skin-integrated flexible electronics are rapidly advancing from short-term use to continuous, long-term wear to meet the demands of health monitoring, wound healing, and skin disease treatment. While three-dimensionally (3D) architected devices offer sensing capabilities and outstanding mechanical performances, the development of a conformal interface between these 3D electronic devices and skin for long-term comfortable wear remains challenging due to their geometric complexity and mechanical fragility. Here, we introduce a multifunctional porous interface that bridges 3D flexible electronics with skin through engineered microporous networks. Such a porous design enhances elastic stretchability and electrical reliability while providing moisture permeability, thermal buffering, impact mitigation, and drug delivery capability. Stiffness reduction and localized pore-wall-shell buckling synergistically underpin the outstanding mechanical resilience under large deformations. The proposed multifunctional porous interface allows development of a 3D closed-loop wound administration patch capable of multimodal sensing and on-demand therapy, markedly accelerating scald wound healing in vivo.

References

  1. 1.Shen, Z., Cheng, X., Luo, X., Tang, Z., Hu, X., Zhang, H., Xiao, Y., Liu, Q., Xu, S., Liu, Z., Bo, R., Yao, S., Zhang, F., & Zhang, Y. (2026). A multifunctional porous interface bridging 3D architected electronics with skin. Science Advances. https://doi.org/10.1126/sciadv.aef0161
Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service